Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 21, Art. 71 (pp. 884-903)    |    2020       

»

Endothelial dysfunction as a link in covid-19 pathogenesis

«Institute of Toxicology» of Federal Medico-Biological Agency of Russia

Brief summary

The main purpose of this work was to substantiate the feasibility and possible directions of influence of pharmacological correction of endothelial dysfunction for the prevention of pathological conditions associated with a new coronavirus infection. The analysis of available literature on endothelial functions is carried out, the study of foreign and domestic experience on possible directions of pharmacological correction of endothelial dysfunction is performed. The review of available literature data on endothelial dysfunction with justification of the role of vascular endothelial damage as one of the central links in the pathogenesis of acute respiratory distress syndrome is presented. The phases of formation of stages of endothelial dysfunction are shown, the mechanisms of endothelial damage in a new coronavirus infection are determined. Possible directions of pharmacological correction of endothelial dysfunction are proposed, which will prevent the risk of complications of a new coronavirus infection, including through the development of pathogenetically justified directions of pharmacotherapy.


Key words

new coronavirus infection, COVID-19, pathogenesis, endothelial dysfunction, viral pneumonia, pharmacotherapy.

Reference list

1. Giannis D., Ziogas I.A., Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J. Clin. Virol. 2020;127. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195278/


2. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020. https://doi.org/10.1515/cclm-2020-0188.


3. Levi M. COVID-19 coagulopathy vs disseminated intravascular coagulation. Blood Adv. 2020;4(12). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322961/


4. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5): 1094-1099. https://doi.org/10.1111/jth.14817.


5. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18(4):786-787. https://doi.org/10.1111/jth.14781.


6. Rekomendacii po diagnostike i intensivnoi terapii sindroma disseminirovannogo vnytrisosydistogo svertivaniya krovi pri virysnom porajenii legkih. Pod red. prof. Vorobeva P.A. i prof. Elikomova V.A. M.: Moskovskoe gorodskoe obshestvo terapevtov; 2020.


7. Borshikova T.I., Epifanceva N.N., Kan S.L., Lizlov A.N. Disfynkciya sosydistogo endoteliya pri tyajeloi cherepno-mozgovoi travme. Medicina v Kyzbasse. 2019;18(2):5-11.


8. Popkova O.V., Kydaeva I.V., Masnavieva L.B. Nekotorie podhodi k opredeleniu disfynkcii endoteliya pri professionalnih zabolevaniyah toksicheskoi etiologii. Medicinskii alfavit. Sovremennaya laboratoriya. 2012;4:57-59.


9. Yavorovskii A.P., Karlova E.A., Sheiman B.S. Toksikokineticheskie mehanizmi formirovaniya endotelialnoi disfynkcii kak rannego klinicheskogo proyavleniya hronicheskogo otravleniya svincom. Serdce i sosydi. 2015;3(51):92-98.


10. Anohina I.P., Klimenko T.V. Patogeneticheskie mehanizmi zavisimosti ot psihoaktivnih veshestv: issledovaniya mediko-biologicheskogo otdela NNC narkologii v 2019 g. Voprosi narkologii. 2020;1(184):39-59.


11. Dubei M.J., Grosh R., Chatterjee S., Biswas P., Chatterjee S., Dubei S. COVID-19 and addiction. Diabetes Metab. Syndr. 2020;14(5):817-823. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282772/


12. Patanavanich R., Glantz S.A. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob. Res. 2020. Accessed May 13, 2020. https://doi.org/10.1101/2020.04.13.20063669


13. Chick J. Alcohol and COVID-19. Alcohol and Alcoholism. 2020. Accessed May 13. https://doi.org/10.1093/alcalc/agaa039.


14. Ermolaeva E.E., Goncharov N.V., Radilov A.S., Glashkina L.M., Kyznecov A.V., Myndykshev I.V., Avdonin P.V., Dobrilko I.A., Rembovskii V.R. Ingibirovanie esteraz i fynkcionalnaya aktivnost makrofagov, trombocitov, endoteliya pri nizkoyrovnevom vozdeistvii diizopropilftorfosfata i fosfakola. Toksikologicheskii vestnik. 2008;2(89):2-7.


15. Vasiluk V.B. Endotelialnaya disfynkciya i ee vozmojnie mehanizmi formirovaniya y personala obektov hraneniya i ynichtojeniya himicheskogo oryjiya. Vestnik Rossiiskoi Voenno-medicinskoi akademii. 2008;1(21):218-224.


16. Korostovceva L.S., Rotar O.P., Konradi A.O. COVID-19: kakovi riski pacientov s arterialnoi gipertenziei? Arterialnaya gipertenziya. 2020;26(2):124-132.


17. Medvedeva S.O., Kolbasnikov S.V. Osobennosti emocionalnih i gemodinamicheskih rasstroistv y bolnih arterialnoi gipertoniei s ojireniem. Medicinskii alfavit. 2016;14(277):38-40.


18. Terenteva N.N., Popova M.A. Ocenka sostoyaniya endotelialnoi disfynkcii pri sochetanii ishemicheskoi bolezni serdca i hronicheskoi obstryktivnoi bolezni legkih. Klinicheskaya medicina. 2015;2(24):36-39.


19. Fedin A.I. Nevrologicheskaya klinicheskaya patologiya, associirovannaya s COVID-19. Nevrologiya i neirohiryrgii. Vostochnaya Evropa. 2020;10(2):312-329.


20. Panina I.U., Rymyancev A.Sh., Menshytina M.A., Achkasova V.V., Degtereva O.A., Tygysheva F.F., Zybina I.M. Osobennosti fynkcii endoteliya pri hronicheskoi bolezni pochek. Obzor literatyri i sobstvennie dannie. Nefrologiya. 2007;11(4):28-46.


21. Melnikova U.S., Makarova T.P. Endotelialnaya disfynkciya kak centralnoe zveno patogeneza hronicheskih boleznei. Kazanskii medicinskii jyrnal. 2015;96(4):659-665.


22. Mayanskaya S.D., Antonov A.R., Popova A.A., Grebenkina I.A. Rannie markeri disfynkcii endoteliya v dinamike razvitiya arterialnoi gipertonii y lic molodogo vozrasta.Kazanskii medicinskii jyrnal. 2009;90(1):32-37.


23. Martinov A.I., Avetyak N.G., Akatova E.V., Gorohovskaya T.N., Romanovskaya G.A. Endotelialnaya disfynkciya i metodi ee opredeleniya. Rossiiskii medicinskii jyrnal. 2005;10(4):94-98.


24. Bobkova I.N., Chebotareva I.V., Rameev V.V., Plieva O.K., Kozlovskaya L.V. Rol endotelialnoi disfynkcii v progressirovanii glomerylonefrita, sovremennie vozmojnosti ee korrekcii. Terapevticheskii arhiv. 2005;77(6):92-96.


25. Koryakin A.M.. Epifanceva N.N. Esheva L.A., Dementeva L.A., Yakimovskih A.V. Povrejdenie, vospalenie sosydistogo endoteliya, giperkoagylyaciya kak faktori riska serdechno-sosydistih zabolevanii y bolnih hronicheskim alkogolizmom. Sibirskii medicinskii jyrnal. 2014;29(4):52-55.


26. Zairatyanc O.V., Samsonova M.V., Mihaleva L.M., Chernyaev A.L., Mishnev O.D., Krypnov N.M., Kalinin D.R. Patologicheskaya anatomiya COVID-19: Atlas. M.: GBY «NIIOZMM DZM»; 2020.


27. Aksenova A.U. Faktor Fon Villebranda i povrejdenie endoteliya: vozmojnaya svyaz s COVID-19. Ekologicheskaya genetika. 2020;18(2):135-138.


28. Wahsh R.El., Amin S., Essa E. Diagnostic value of von Willebrand factor (VWF) in patients suffering from respiratory distress. Eur Respir J. 2011;38:1686.


29. Higashi Y., Noma K., Yoshizumi M., Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circulation J. 2009;3:411-415.


30. Guzik T.J., Harrison D.G. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discovery Today. 2006;11-12:524-526.


31. Dremina N.N., Shyrigin M.G., Shyrigina I.A. Endotelini v norme i patologii. Mejdynarodnii jyrnal prikladnih i fyndamentalnih issledovanii. 2016;10(2):210-214.


32. Galenko A.S., Shylenin S.N. Sposobi nemedikamentoznoi i farmakologicheskoi korrekcii endotelialnoi disfynkcii. FARMindeks-Praktik. 2006;vip.10:2-10.


33. Disfynkciya endoteliya. Prichini, mehanizmi, farmakologicheskaya korrekciya. Pod red. Petrisheva N.N. SPb.: Izdatelstvo SPBGMY; 2003.


34. Karkishenko V.N., Karkishenko N.N., Shystov E.B. Farmakologicheskie osnovi terapii. Tezayrys. M., SPb.: Aising, 2018.


35. Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. 2020. https://doi.org/10.1016/j.apsb.2020.04.008.


36. Racionalnaya farmakoterapiya v gepatologii: rykovodstvo dlya vrachei. Pod red. Byerova A.O. M.: Littera; 2009.